Novartis pulls Pluvicto prostate cancer label expansion filing in the EU

Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain favor with the European regulators for ...